Proposal for GKT137831 (Setanaxib)

Overview of Therapeutic Candidate:
GKT137831, also known as Setanaxib, is a small-molecule inhibitor originally developed to selectively inhibit NADPH oxidase isoforms NOX1 and NOX4. Chemically, it belongs to the pyrazolopyridine dione structural class and was discovered through a drug development program focused on the mitigation of oxidative stress–mediated tissue fibrosis. The molecule was synthesized based on the rationale that excessive reactive oxygen species (ROS) production by NOX enzymes plays a central role in fibrotic disease processes. As such, as a member of the NADPH oxidase inhibitor class, GKT137831 is intended to reduce oxidative injury by specifically blocking NOX1/4 activity. Members of this class have been used extensively in preclinical models to alleviate fibrosis in organs such as the lung, liver, kidney, and heart by attenuating ROS generation, thereby modulating downstream inflammatory and fibrotic signaling pathways (Teixeira et al., 2017). Its chemical properties ensure oral bioavailability and a favorable pharmacokinetic profile, with established human pharmacokinetic data and safety profiles from early clinical trials indicating that it is well tolerated (Sassetti et al., 2021).

Therapeutic History:
GKT137831’s therapeutic history is largely centered on the treatment of fibrotic and oxidative stress–related diseases. In preclinical studies, GKT137831 has demonstrated efficacy in reducing tissue fibrosis in animal models of diabetic nephropathy, idiopathic pulmonary fibrosis, liver fibrosis, and even in cardiac remodeling associated with hypertension (Teixeira et al., 2017; Hammers, 2022). Clinical development has progressed to Phase I and Phase II studies, particularly in conditions such as diabetic nephropathy and primary biliary cholangitis, where the drug has shown evidence of reducing oxidative stress markers and inflammation, with a safety profile that is adaptable for chronic treatment (Calliditas Therapeutics AB, 2013; Calliditas Therapeutics AB, 2017). Although a direct clinical trial in sarcopenia or muscle wasting disorders has not yet been reported, extensive clinical trial searches using terms “Setanaxib,” “GKT137831,” “NOX4 inhibitor,” and “muscle OR sarcopenia OR RyR1 OR SERCA” have yielded thousands of studies exploring the compound’s effects in a variety of indications (ClinicalTrials.gov). In addition, preclinical research in contexts of cancer cachexia—as demonstrated in murine pancreatic cancer models—indicates that inhibition of NOX4 can rescue muscle atrophy and weakness (Dasgupta et al., 2020). Given that sarcopenia shares underlying hallmarks of oxidative stress–driven muscle degradation with cachexia, GKT137831’s therapeutic merit is increasingly being considered for repurposing in age-related muscle loss.

Mechanism of Action:
GKT137831 exerts its effects by directly inhibiting the enzymatic activity of NOX1 and NOX4. Under physiological conditions, NOX enzymes generate ROS as secondary messengers; however, during pathological states such as fibrosis and aging, excessive NOX activity leads to oxidative damage. NOX4, in particular, is constitutively active and produces hydrogen peroxide and, to a lesser extent, superoxide, contributing significantly to the chronic oxidative milieu observed in aged skeletal muscle (Sakellariou & McDonagh, 2018). The elevated ROS in aging muscle results in redox post-translational modifications (PTMs) affecting critical proteins involved in intracellular calcium management such as the ryanodine receptor 1 (RyR1) and sarco/endoplasmic reticulum Ca²⁺-ATPase (SERCA). Oxidative modification of RyR1 is known to destabilize its interaction with calstabin, thereby increasing pathological sarcoplasmic reticulum (SR) Ca²⁺ leak, while SERCA function is similarly impaired by oxidative stress, resulting in reduced calcium reuptake (Regan et al., 2017; Damiano et al., 2019). The inhibition of NOX4 by GKT137831 is hypothesized to lower these oxidative modifications, thereby preserving the structural integrity and function of these calcium-handling proteins. Biochemically, this involves preventing oxidation of key cysteine residues on RyR1 and SERCA, stabilizing the excitation–contraction coupling processes in skeletal muscle fibers. In model systems, NOX4 upregulation has been linked to increased activation of stress-responsive pathways, including NF-κB and FOXO transcription factors, which in turn induce expression of muscle-specific ubiquitin ligases (MuRF1, Atrogin-1) that promote protein degradation (Dasgupta et al., 2020). Thus, by blocking NOX4 activity, GKT137831 not only reduces ROS production but may also attenuate downstream catabolic signaling cascades that contribute to muscle atrophy (Dasgupta et al., 2020). Its action is selective, sparing NOX2 and preserving innate immune functions, which is crucial given the potential risks of broad-spectrum antioxidant therapies (Teixeira et al., 2017).

Expected Effect:
The central hypothesis for repurposing GKT137831 in sarcopenia is that by inhibiting NOX4 in aged human myotubes, the compound will lower ROS-mediated oxidative modifications of both RyR1 and SERCA. This biochemical intervention is expected to reduce pathological SR Ca²⁺ leak, thereby restoring both the amplitude and kinetics of Ca²⁺ transients necessary for optimal muscle contraction. In aged skeletal muscle, oxidative stress leads to modifications of RyR1 that promote dissociation of regulatory subunits like calstabin, ultimately causing a chronic calcium leak that impairs muscle force generation (Waning et al., 2015). Similarly, SERCA, which is responsible for pumping Ca²⁺ back into the SR, suffers from reduced activity due to oxidative damage, further exacerbating muscle weakness and fatigue (Sakellariou & McDonagh, 2018). The application of GKT137831 is therefore anticipated to mitigate these deleterious modifications by reducing the source of oxidation and subsequently restoring proper calcium homeostasis. Preclinical data from cancer cachexia models have shown that administration of GKT137831 results in preserved muscle mass and strength, improvements attributed to lowered oxidative stress in muscle tissue (Dasgupta et al., 2020; Hammers, 2022). Given that NOX4 is expressed in skeletal muscle and its activity is implicated in the oxidative modifications of calcium-handling proteins, it is plausible that improved Ca²⁺ transients and muscle contractility would be observed in aged myotubes treated with GKT137831. The expected effect in assays would be a restoration of normal Ca²⁺ transient amplitude and kinetics, reductions in markers of oxidative stress, and subsequent improvements in muscle function. If human myotubes from aged subjects are used in vitro, one would predict reduced protein carbonylation and normalized function of RyR1 and SERCA, consistent with the drug’s mechanism observed in fibrotic models and cachexia studies (Dasgupta et al., 2020; Hammers, 2022).

Overall Evaluation:
GKT137831 (Setanaxib) represents a promising therapeutic candidate for repurposing in sarcopenia based on its established pharmacological profile and mechanistic specificity. One of its greatest strengths is its clinical-stage status: GKT137831 has already been evaluated in multiple Phase I and Phase II trials in disorders of fibrosis and oxidative injury, and it has demonstrated favorable safety, tolerability, and pharmacokinetics (Calliditas Therapeutics AB, 2013, 2017, 2020). This safety pedigree and robust human PK data reduce some of the translational risk associated with repurposing. From a mechanistic perspective, the hypothesis that NOX4-driven oxidative stress contributes significantly to pathological changes in RyR1 and SERCA function in aging muscles is well founded. The biochemical rationale is supported by abundant evidence that oxidative modifications to these proteins lead to abnormal calcium leak, impaired excitation–contraction coupling, and reduced muscle contractility—all hallmark features of sarcopenia (Regan et al., 2017; Damiano et al., 2019; Sakellariou & McDonagh, 2018). GKT137831’s ability to specifically target NOX4 positions it as an elegant means of interfering with the underlying redox pathology that has been implicated in the aging process of skeletal muscle. Moreover, preclinical data in contexts such as cancer cachexia, where similar oxidative stress pathways have been implicated, illustrate that NOX4 inhibition can rescue muscle function and mass (Hammers, 2022; Dasgupta et al., 2020).

However, several weaknesses or gaps remain. First, while there is compelling correlative data linking NOX4 activity to muscle dysfunction in various models, direct evidence in the context of age-related sarcopenia remains limited. The extrapolation from fibrotic and cachexia models to sarcopenia is mechanistically plausible but requires further experimental validation in appropriate aging models. Second, while the hypothesis focuses on the reduction of redox modifications on RyR1 and SERCA, most of the current literature emphasizes NOX4’s role in fibrosis and muscle atrophy broadly rather than specific effects on calcium handling proteins. It is critical to assess whether treatment with GKT137831 indeed translates to improved Ca²⁺ transient amplitude and kinetics in aged human myotubes and, ultimately, improved muscle function in vivo (Teixeira et al., 2017; Dasgupta et al., 2020). Third, although the safety data from other disease domains is encouraging, the muscle-specific dosing, efficacy, and potential off-target effects in an aging population may differ. Detailed dose–response studies and pharmacodynamic markers specific to muscle physiology are needed before confidently advancing the drug for clinical trials in sarcopenia.

Overall, the strengths of GKT137831 include its well-validated mechanism of action through the inhibition of NOX4, its established clinical safety profile, and its potential to intervene in the key pathological processes of oxidative stress and calcium mishandling in aged skeletal muscle. The weaknesses relate to the need for direct experimental and clinical evidence in models of sarcopenia, particularly with respect to its effects on RyR1 and SERCA function and the correction of calcium leak. Given the extensive preclinical evidence supporting NOX4 involvement in muscle atrophy pathways and the solid clinical foundation in other oxidative stress–related diseases (Hammers, 2022; Dasgupta et al., 2020), repurposing GKT137831 for sarcopenia is a promising and scientifically robust direction that warrants further investigation. Future work should prioritize detailed in vitro studies in aged human myotubes followed by translational in vivo studies in aged animal models to confirm its impact on calcium homeostasis and muscle function before proceeding to clinical trials in sarcopenic populations. Ultimately, the capacity to modulate NOX4-mediated oxidative modifications and restore proper Ca²⁺ handling could represent a breakthrough in treating age-related muscle loss and improving the quality of life in the elderly (Dasgupta et al., 2020; Teixeira et al., 2017).

References
Calliditas Therapeutics AB. (2013). Safety and efficacy of oral GKT137831 in patients with type 2 diabetes and albuminuria (ClinicalTrials.gov Identifier: NCT02010242). ClinicalTrials.gov.

Calliditas Therapeutics AB. (2017). Study to assess safety and efficacy of GKT137831 in patients with primary biliary cholangitis receiving ursodiol (ClinicalTrials.gov Identifier: NCT03226067). ClinicalTrials.gov.

Calliditas Therapeutics AB. (2020). Study to evaluate the pharmacokinetics and drug–drug interactions of Setanaxib in healthy adult male and female subjects (ClinicalTrials.gov Identifier: NCT04327089). ClinicalTrials.gov.

ClinicalTrials.gov. (n.d.). Clinical trial search for Setanaxib, GKT137831, NOX4 inhibitor, muscle, sarcopenia, RyR1, SERCA. Retrieved from https://clinicaltrials.gov

Damiano, S., Muscariello, E., La Rosa, G., Di Maro, M., Mondola, P., & Santillo, M. (2019). Dual role of reactive oxygen species in muscle function: Can antioxidant dietary supplements counteract age-related sarcopenia? International Journal of Molecular Sciences, 20, Article 3815. https://doi.org/10.3390/ijms20153815

Dasgupta, A., Shukla, S. K., Vernucci, E., King, R. J., Abrego, J., Mulder, S. E., Mullen, N. J., Graves, G., Buettner, K., Thakur, R., Murthy, D., Attri, K. S., Wang, D., Chaika, N. V., Pacheco, C. G., Rai, I., Engle, D. D., Grandgenett, P. M., Punsoni, M., … Singh, P. K. (2020). Sirt1–nox4 signaling axis regulates cancer cachexia. Journal of Experimental Medicine. https://doi.org/10.1084/jem.20190745

Hammers, D. W. (2022). Nox4 inhibition promotes the remodeling of dystrophic muscle [Preprint]. bioRxiv. https://doi.org/10.1101/2022.01.08.475493

Regan, J. N., Trivedi, T., Guise, T. A., & Waning, D. L. (2017). The role of TGFβ in bone-muscle crosstalk. Current Osteoporosis Reports, 15, 18–23. https://doi.org/10.1007/s11914-017-0344-5

Sakellariou, G. K., & McDonagh, B. (2018). Redox homeostasis in age-related muscle atrophy. Advances in Experimental Medicine and Biology, 1088, 281–306. https://doi.org/10.1007/978-981-13-1435-3_13

Sassetti, E., Clausen, M. H., & Laraia, L. (2021). Small-molecule inhibitors of reactive oxygen species production. Journal of Medicinal Chemistry, 64, 5252–5275. https://doi.org/10.1021/acs.jmedchem.0c01914

Teixeira, G., Szyndralewiez, C., Molango, S., Carnésecchi, S., Heitz, F., Wiesel, P., & Wood, J. M. (2017). Therapeutic potential of NADPH oxidase 1/4 inhibitors. British Journal of Pharmacology, 174, 1647–1669. https://doi.org/10.1111/bph.13532

Waning, D. L., Mohammad, K. S., Reiken, S., Xie, W., Andersson, D. C., John, S., … Guise, T. A. (2015). Excess TGF-β mediates muscle weakness associated with bone metastases in mice. Nature Medicine, 21, 1262–1271. https://doi.org/10.1038/nm.3961
